
Estrella Immunopharma’s ARTEMIS® T-Cell Therapy Leads to Complete Remission in First Patient
Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW), a clinical-stage biopharmaceutical company specializing in ARTEMIS® T-cell therapies targeting CD19 and CD22 for cancer and autoimmune disease treatment, has announced that the first patient in the Phase I/II STARLIGHT-1 clinical trial achieved complete…












